Literature DB >> 18667373

Lights and shadows of the tumoral marker CA-125 in ovarian cancer.

A Sánchez Muñoz, A González Martín, C Mendiola Fernández.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18667373     DOI： 10.1007/s12094-008-0231-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  27 in total

1.  Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

Authors:  S M Crawford; J Peace
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

2.  Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

Authors:  Usha Menon; Steven J Skates; Sara Lewis; Adam N Rosenthal; Barnaby Rufford; Karen Sibley; Nicola Macdonald; Anne Dawnay; Arjun Jeyarajah; Robert C Bast; David Oram; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

3.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors:  G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

Authors:  I Jacobs; A P Davies; J Bridges; I Stabile; T Fay; A Lower; J G Grudzinskas; D Oram
Journal:  BMJ       Date:  1993-04-17

Review 5.  Tumor markers in the management of patients with ovarian cancer.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Cancer Treat Rev       Date:  1995-05       Impact factor: 12.111

6.  Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.

Authors:  O Kierkegaard; O Mogensen; B Mogensen; A Jakobsen
Journal:  Gynecol Oncol       Date:  1995-11       Impact factor: 5.482

7.  CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery.

Authors:  C A Yedema; P Kenemans; C M Thomas; L F Massuger; T Wobbes; R Verstraeten; G J van Kamp; J Hilgers
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.

Authors:  Maurie Markman; P Y Liu; Mace L Rothenberg; Bradley J Monk; Mark Brady; David S Alberts
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

Review 9.  NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.

Authors: 
Journal:  JAMA       Date:  1995-02-08       Impact factor: 56.272

Review 10.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

Authors:  Mark Harries; Martin Gore
Journal:  Lancet Oncol       Date:  2002-09       Impact factor: 41.316
View more
  1 in total

1.  Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.

Authors:  Cai-Xia Zhu; Wei Xiong; Ma-Lie Wang; Juan Yang; Hui-Juan Shi; Han-Qing Chen; Gang Niu
Journal:  J Int Med Res       Date:  2017-09-12       Impact factor: 1.671
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.